Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Carcinoma, Non-Small-Cell Lung 84Breast Neoplasms 34Colorectal Neoplasms 26Lung Neoplasms 23Rectal Neoplasms 22Neoplasms 21Esophageal Squamous Cell Carcinoma 20Neoplasm Metastasis 19Esophageal Neoplasms 19Head and Neck Neoplasms 17Stomach Neoplasms 15Pancreatic Neoplasms 15Squamous Cell Carcinoma of Head and Neck 14Triple Negative Breast Neoplasms 12Small Cell Lung Carcinoma 12Ovarian Neoplasms 11Recurrence 10Nasopharyngeal Carcinoma 10Carcinoma, Squamous Cell 10Uterine Cervical Neoplasms 9Leukemia, Myeloid, Acute 9Colonic Neoplasms 9Glioblastoma 8Prostatic Neoplasms 7Lymphoma, Large B-Cell, Diffuse 7Lymphoma 7Sarcoma 6Precursor Cell Lymphoblastic Leukemia-Lymphoma 6Melanoma 6Lymphoma, Non-Hodgkin 6

Interventions

anlotinib 1Radiotherapy 1Immunotherapy 1Drug Therapy 1Docetaxel 1Cisplatin 1Chemoradiotherapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Locally Advanced Non-small Cell Lung Cancer × Drug Therapy × Clear all
NCT05481775 2022-11-21

Evaluating Efficacy and Safety of Anlotinib Combined With Concurrent Chemoradiotherapy Followed by Consolidation Immunotherapy for Locally Advanced Non-small Cell Lung Cancer

Sun Yat-sen University

Phase 2 Withdrawn
Thoracic

Locally Advanced Non-small Cell Lung Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡